Across advanced and early stage EGFRm NSCLC Precision that makes the unprecedented possible

Resected EGFRm NSCLC (Stage IB-IIIA)* 80% reduced risk of recurrence or death vs placebo HR=0.20 (99.12% CI: 0.14, 0.30; P<0.001)1†

In resected EGFRm NSCLC See adjuvant TAGRISSO data (ADAURA) Explore the ADAURA publication in the New England Journal of Medicine

Advanced EGFRm NSCLC 38.6 vs 31.8 months median OS vs gefitinib/erlotinib HR=0.80 (95.05% CI: 0.641, 0.997; P=0.0462)2

In advanced EGFRm NSCLC See first-line TAGRISSO data (FLAURA) Watch Professor Ramalingam present the FLAURA OS data

CI=confidence interval; DFS=disease-free survival; HR=hazard ratio; NC=not calculated; OS=overall survival; PFS=progression-free survival.


*In patients with Stage II to IIIA resected EGFRm NSCLC (primary endpoint), adjuvant TAGRISSO reduced the risk of recurrence or death by 83% vs placebo (HR=0.17 [99.06% CI: 0.11, 0.26]; P<0.001). Median DFS was not reached in the TAGRISSO arm (95% CI: 38.8, NC) vs 19.6 months in the placebo arm (95% CI: 16.6, 24.5).1

Median DFS: not reached in the adjuvant TAGRISSO arm.1

PFS was the primary endpoint. OS was a prespecified secondary endpoint; statistically significant HR for OS was demonstrated (HR=0.799; 95.05% CI: 0.641, 0.997; P=0.0462).2,3

TAGRISSO AS MONOTHERAPY IS INDICATED FOR:
  • the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
  • the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations.
  • the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.

references: 1. Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non–small-cell lung cancer. N Engl J Med. 2020;383(18):1711-1723. 2. AstraZeneca Pharmaceuticals. TAGRISSO® (osimertinib). Summary of Product Characteristics, 2021. 3. Soria JC, Ohe Y, Vansteenkiste J, et al; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113-125.